Checkpoint Therapeutics, Inc.
Checkpoint Therapeutics, Inc. (CKPT): 8 pipeline candidates · ~9 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.6 months
D/E 1.10 · 0% dilution
Lead: Approved
8 candidates
N/A
N/A
A transparent, data-derived signal for Checkpoint Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$33.0M
Quarterly Burn
$11.7M
Runway
8.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| anti-caix | Preclinical |
| anti-caix antibody | Preclinical |
| ck-103 | Preclinical |
| ck-302 | Preclinical |
| cosibelimab | Phase 1 |
| ibc-ab002 | Phase 1 |
| olafertinib | Phase 3 |
| unloxcyt | Approved |
Frequently asked questions
How many drug candidates are in Checkpoint Therapeutics, Inc.'s pipeline?
Checkpoint Therapeutics, Inc. (CKPT) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Checkpoint Therapeutics, Inc.'s lead drug candidate?
Checkpoint Therapeutics, Inc.'s most advanced tracked candidate is anti-caix (Preclinical) for renal cell carcinoma ("RCC").
What is Checkpoint Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Checkpoint Therapeutics, Inc. has approximately 8.6 months of cash runway.
Who is the CEO of Checkpoint Therapeutics, Inc.?
Sawyer Road is the chief executive officer of Checkpoint Therapeutics, Inc. (CKPT).
Get the full picture on Checkpoint Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.